HAE Insider Trading
HAEMONETICS CORP | Surgical & Medical Instruments & Apparatus
Comprehensive Trading Performance Summary
The investment history of corporate insiders at HAEMONETICS CORP provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Surgical & Medical Instruments & Apparatus sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2013-10-15 21:07 | 2013-10-14 | Kelly Michael P | Officer - President, Global Markets | OPT+S | $40.41 | 1,400 | $56,568 | 11,337 | 0.0% |
| 2013-10-02 20:04 | 2013-10-01 | CONCANNON BRIAN | Director, Officer - President & CEO | OPT+S | $39.88 | 3,000 | $119,647 | 115,798 | 0.0% |
| 2013-09-18 01:25 | 2013-09-13 | Kelly Michael P | Officer - President, Global Markets | OPT+S | $40.36 | 1,400 | $56,507 | 11,337 | 0.0% |
| 2013-09-05 01:17 | 2013-09-03 | CONCANNON BRIAN | Director, Officer - President & CEO | OPT+S | $39.87 | 13,000 | $518,285 | 115,798 | 0.0% |
| 2013-08-06 01:11 | 2013-08-01 | CONCANNON BRIAN | Director, Officer - President & CEO | OPT+S | $42.24 | 13,000 | $549,143 | 115,798 | 0.0% |
| 2013-07-16 23:31 | 2013-07-12 | Kelly Michael P | Officer - President, Global Markets | OPT+S | $44.10 | 1,400 | $61,740 | 11,736 | 0.0% |
| 2013-07-03 21:14 | 2013-07-01 | CONCANNON BRIAN | Director, Officer - President & CEO | OPT+S | $41.87 | 13,000 | $544,341 | 115,798 | 0.0% |
| 2013-06-20 23:42 | 2013-06-18 | LINDOP CHRISTOPHER J | Officer - CFO & EVP Business Development | OPT+S | $42.50 | 68,628 | $2,916,690 | 30,414 | 0.0% |
| 2013-06-18 23:38 | 2013-06-14 | Kelly Michael P | Officer - President, Global Markets | OPT+S | $42.17 | 1,400 | $59,034 | 11,736 | 0.0% |
| 2013-06-05 23:26 | 2013-06-03 | CONCANNON BRIAN | Director, Officer - President & CEO | OPT+S | $41.15 | 13,000 | $534,955 | 115,798 | 0.0% |
| 2013-05-23 23:59 | 2013-05-21 | LINDOP CHRISTOPHER J | Officer - CFO & EVP Business Development | OPT+S | $42.00 | 42,882 | $1,801,044 | 31,110 | 0.0% |
| 2013-05-17 01:21 | 2013-05-14 | Kelly Michael P | Officer - President, Global Markets | OPT+S | $39.66 | 1,400 | $55,526 | 11,736 | 0.0% |
| 2013-05-07 23:17 | 2013-05-03 | BEST LAWRENCE C | Director | OPT+S | $38.32 | 12,000 | $459,830 | 8,352 | 0.0% |
| 2013-05-03 02:18 | 2013-04-30 | Helsel Dave | Officer - EVP, Global Manufacturing | BUY | $32.73 | 272 | $8,901 | 6,856 | +4.1% |
| 2013-05-03 02:18 | 2013-04-30 | Jesse Sandra | Officer - Chief Legal Officer | BUY | $32.73 | 614 | $20,093 | 8,680 | +7.6% |
| 2013-05-03 02:19 | 2013-04-30 | White Jonathan | Officer - Chief Scientific and Technogy | BUY | $32.73 | 615 | $20,126 | 25,342 | +2.5% |
| 2013-05-03 02:19 | 2013-04-30 | LINDOP CHRISTOPHER J | Officer - CFO & EVP Business Development | BUY | $32.73 | 412 | $13,483 | 31,522 | +1.3% |
| 2013-05-03 02:18 | 2013-04-30 | ALLEN PETER M | Officer - President, Global Plasma | BUY | $32.73 | 451 | $14,759 | 26,797 | +1.7% |
| 2013-05-02 22:19 | 2013-05-01 | CONCANNON BRIAN | Director, Officer - President & CEO | OPT+S | $38.66 | 13,000 | $502,605 | 115,798 | 0.0% |
| 2013-05-03 02:19 | 2013-04-30 | FORISH JOSEPH J | Officer - VP, Human Resources | BUY | $32.73 | 615 | $20,126 | 17,279 | +3.7% |
| 2013-05-03 02:19 | 2013-04-30 | HANLON SUSAN M | Officer - VP Finance | BUY | $32.73 | 245 | $8,018 | 16,751 | +1.5% |
| 2013-04-16 22:30 | 2013-04-12 | Kelly Michael P | Officer - President, Global Markets | OPT+S | $40.93 | 1,400 | $57,295 | 11,736 | 0.0% |
| 2013-04-05 23:23 | 2013-04-03 | ALLEN PETER M | Officer - President, Global Plasma | OPT+S | $41.44 | 22,828 | $946,004 | 26,346 | 0.0% |
| 2013-04-04 00:10 | 2013-04-01 | CONCANNON BRIAN | Director, Officer - President & CEO | OPT+S | $41.94 | 10,288 | $431,472 | 116,286 | 0.0% |
| 2013-03-18 22:55 | 2013-03-14 | Kelly Michael P | Officer - President, Global Markets | OPT+S | $41.14 | 1,400 | $57,589 | 11,736 | 0.0% |
| 2013-03-05 21:38 | 2013-03-01 | CONCANNON BRIAN | Director, Officer - President & CEO | OPT+S | $41.06 | 13,000 | $533,811 | 116,286 | 0.0% |
| 2013-03-01 00:36 | 2013-02-26 | White Jonathan | Officer - VP Research and Development | SELL | $40.69 | 3,000 | $122,070 | 0 | -100.0% |
| 2013-02-20 01:25 | 2013-02-14 | Kelly Michael P | Officer - President, Global Markets | OPT+S | $41.71 | 1,400 | $58,394 | 11,736 | 0.0% |
| 2013-02-05 20:35 | 2013-02-01 | CONCANNON BRIAN | Director, Officer - President & CEO | OPT+S | $41.96 | 13,000 | $545,466 | 116,286 | 0.0% |
| 2013-01-17 00:17 | 2013-01-14 | Kelly Michael P | Officer - President, Global Markets | OPT+S | $42.29 | 1,400 | $59,211 | 11,736 | 0.0% |
| 2013-01-09 01:16 | 2013-01-04 | ALLEN PETER M | Officer - President, Global Plasma | OPT+S | $41.62 | 53,288 | $2,217,815 | 26,346 | 0.0% |
| 2013-01-09 01:17 | 2013-01-07 | CONCANNON BRIAN | Director, Officer - President & CEO | OPT+S | $41.47 | 13,000 | $539,172 | 116,286 | 0.0% |
| 2013-01-09 01:17 | 2013-01-04 | HANLON SUSAN M | Officer - VP Finance | OPT+S | $41.66 | 10,000 | $416,570 | 16,506 | 0.0% |
| 2012-12-17 23:47 | 2012-12-13 | GELBMAN RONALD G | Director | OPT+S | $40.07 | 11,310 | $453,202 | 37,524 | 0.0% |
| 2012-12-13 15:48 | 2012-12-11 | Nighan Warren JR | Officer - VP WW Q&R Affairs | OPT+S | $40.21 | 8,258 | $332,072 | 7,908 | 0.0% |
| 2012-12-05 22:03 | 2012-12-03 | CONCANNON BRIAN | Director, Officer - President & CEO | OPT+S | $40.75 | 13,000 | $529,738 | 116,286 | 0.0% |
| 2012-11-21 21:13 | 2012-11-20 | LINDOP CHRISTOPHER J | Officer - CFO & Vice President of | SELL | $80.95 | 278 | $22,504 | 15,198 | -1.8% |
| 2012-11-21 21:12 | 2012-11-19 | KROLL MARK W | Director | OPT+S | $80.13 | 4,592 | $367,957 | 4,176 | 0.0% |
| 2012-11-21 21:13 | 2012-11-19 | MERRIMAN RONALD | Director | SELL | $80.98 | 1,008 | $81,628 | 5,168 | -16.3% |
| 2012-11-20 18:59 | 2012-11-16 | KROLL MARK W | Director | OPT+S | $79.67 | 6,000 | $478,033 | 4,176 | 0.0% |
| 2012-11-15 01:35 | 2012-11-12 | GRANADILLO PEDRO P | Director | OPT+S | $80.40 | 16,000 | $1,286,341 | 6,626 | 0.0% |
| 2012-11-06 01:59 | 2012-11-01 | Helsel Dave | Officer - VP, Global Manufacturing | BUY | $61.46 | 144 | $8,850 | 3,456 | +4.3% |
| 2012-11-06 01:59 | 2012-11-01 | Jesse Sandra | Officer - VP & CLO | BUY | $61.46 | 285 | $17,515 | 4,033 | +7.6% |
| 2012-11-06 02:00 | 2012-11-01 | LINDOP CHRISTOPHER J | Officer - CFO & Vice President of | BUY | $61.46 | 132 | $8,112 | 15,476 | +0.9% |
| 2012-11-06 01:58 | 2012-11-01 | ALLEN PETER M | Officer - President, Global Plasma | BUY | $61.46 | 113 | $6,944 | 13,173 | +0.9% |
| 2012-11-06 01:59 | 2012-11-01 | CONCANNON BRIAN | Director, Officer - President & CEO | OPT+S | $81.82 | 6,500 | $531,860 | 58,143 | 0.0% |
| 2012-11-06 01:59 | 2012-11-01 | HANLON SUSAN M | Officer - VP Finance | BUY | $61.46 | 119 | $7,313 | 8,253 | +1.5% |
| 2012-10-10 18:10 | 2012-10-08 | ALLEN PETER M | Officer - President, Global Plasma | OPT+S | $81.09 | 10,000 | $810,933 | 11,910 | 0.0% |
| 2012-10-04 00:14 | 2012-10-01 | CONCANNON BRIAN | Director, Officer - President & CEO | OPT+S | $80.73 | 6,500 | $524,720 | 48,171 | 0.0% |
| 2012-09-17 18:47 | 2012-09-13 | FORISH JOSEPH J | Officer - VP, Human Resources | OPT+S | $80.00 | 5,373 | $429,840 | 8,497 | 0.0% |
How to Interpret $HAE Trades
Not every insider transaction in HAEMONETICS CORP is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $HAE shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for HAE
Insider activity data for HAEMONETICS CORP is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $HAE, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.